Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Rex Fang & Innovation Equity Premium Income ETFTrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Rex Fang & Innovation Equity Premium Income ETF vs Zimmer Biomet Holdings Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.92, while Zimmer Biomet Holdings Inc trades at $96.19 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Zimmer Biomet Holdings Inc is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

FEPIZBH
Sector
Income / Options OverlayHealth
52-Week High
$49.54$107.71
52-Week Low
$37.98$79.58
Market Cap
$18.55B
Enterprise Value
$25.61B
Dividend Yield
0.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rex Fang & Innovation Equity Premium Income ETF

FEPI, the REX FANG & Innovation Equity Premium Income ETF, trades at $41.88, showing minimal daily movement with a 0.02% gain. The technical outlook is bullish based on moving averages, though oscillators are neutral. The ETF employs a covered call strategy on a concentrated basket of AI and mega-cap tech stocks, generating a high yield through weekly dividends, with recent payouts around $0.20-$0.21 per share. Recent news highlights its transition to weekly distributions and investor interest due to its aggressive income approach.

FEPI offers a high-yield opportunity through its covered call strategy, appealing for income-focused investors, but faces risks from NAV erosion in downturns and limited upside potential. The concentrated portfolio of volatile tech names increases exposure to sector-specific swings, requiring careful risk assessment for long-term holdings.

Zimmer Biomet Holdings Inc

ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.

The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.

Returns comparison

Trailing returns across standard periods

About Rex Fang & Innovation Equity Premium Income ETF

FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.

Read more on FEPI

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH